ASH24: Disease-Modifying Therapies Remain Underused in Sickle Cell Disease in USA

The underuse of disease-modifying therapies in sickle cell disease (SCD) reflects systemic healthcare barriers in the USA. These include gaps in provider education, limited patient access to specialized care, and socioeconomic disparities that disproportionately impact individuals with SCD. This calls to action because SCD is the most common inherited blood disorder in the United States.